ViCentra's Kaleido is "the smallest, thinnest, lightest, most precise insulin patch pump in its class," CEO Tom Arnold said ...

Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...

ARLINGTON, VA / ACCESS Newswire / August 13, 2025 / FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 ...

Dexcom raised its sales expectations for 2025 amid expanding access to its glucose sensors for people with Type 2 diabetes. The company raised its revenue forecast to a range of $4.6 billion to about ...

The company’s sensor and other revenue, which represents 97% of total revenue, jumped 18% YoY to $1.12 billion, offsetting a 31% decline in hardware revenue. "During the quarter, Dexcom delivered ...

Medicare Part B typically covers continuous glucose monitors (CGMs) like the Dexcom G7, as they are Food and Drug Administration (FDA)-approved durable medical equipment items. To get a Dexcom G7 CGM ...

Abstract: Minimally-invasive continuous glucose monitoring (CGM) sensors are used in diabetes therapy to monitor interstitial glucose (IG) concentration almost continuously (e.g. every 5 min) and ...

An interdisciplinary team of researchers from various Chinese universities have developed a miniature-sized continuous glucose monitoring system that works as effectively as market-leading systems.

Continuous glucose monitors (CGMs) are monitoring devices people with diabetes use. They apply them directly to the skin and monitor their blood glucose (blood sugar) readings in real time. Dexcom's ...

SAN DIEGO – Dexcom has received clearance from the U.S. Food and Drug Administration for its Stelo by Dexcom, a continuous glucose monitor that will be available for people with Type 2 diabetes ...

The Stelo glucose monitor. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) Chair, President and CEO Kevin Sayer says that, in 2019, he gave a speech announcing the company’s first $1 billion year.

Recent integrations between continuous glucose monitors and insulin pumps are allowing diabetes tech users to choose between more options. Tandem t:slim X2 users can now use either the FreeStyle Libre ...